Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF, a target in melanoma: implications for solid tumor drug development.

Cancer - 1 Nov 2010

Flaherty Keith T, McArthur Grant

Abstract excerpt

The successful translation of therapies targeting signal-transduction pathways that are activated by oncogenes has provided a model for molecularly targeted therapy, and the identification of mutations in v-raf murine sarcoma viral oncogene homolog B1 (BRAF), a serine/threonine kinase, has turned the attention of the melanoma field toward this concept. The current review indicated that BRAF represents an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Melanoma
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Drug Delivery Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Enzyme Activation

Share to MAP Kinase Signaling System

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Identifiers

PMID: 20629085
DOI: 10.1002/cncr.25261

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF, a target in melanoma: implications for solid tumor drug development.PMID 20629085Read ↗

BRAF as a potential therapeutic target in melanoma and other malignancies.Semantic proximity Read ↗

Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials.Semantic proximity Read ↗

Evolution of Molecular Targets in Melanoma Treatment.Semantic proximity Read ↗

New drug targets in metastatic melanoma.Semantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

Emerging targeted therapies for melanoma.Semantic proximity Read ↗

Inside life of melanoma cell signaling, molecular insights, and therapeutic targets.Semantic proximity Read ↗

Immunotherapy in Melanoma: A Dynamic Frontier in Cancer Treatment : Author List.Semantic proximity Read ↗

Narrative review: BRAF opens the door for therapeutic advances in melanoma.Semantic proximity Read ↗

Targeted Therapy Innovations for Melanoma.Semantic proximity Read ↗

Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.Semantic proximity Read ↗

Beyond BRAF: where next for melanoma therapy?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.